Bookmark
Forward
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Gemma Azaceta, Maria J Calasanz, Victoria Dourdil, Elena Bonafonte, Isabel Izquierdo, Luis Palomera
Leukemia & lymphoma 2010 Oct
Sizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Gemma Azaceta, Maria J Calasanz, Victoria Dourdil, Elena Bonafonte, Isabel Izquierdo, Luis Palomera.
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Leukemia & lymphoma.
2010 Oct;51(10):1941-3
Mesh Tags
Aged, 80 and over
Amino Acid Substitution
Antineoplastic Agents
Chromosome Deletion
Chromosomes, Human, Pair 5
Female
Humans
Janus Kinase 2
Mutation
Myelodysplastic Syndromes
Thalidomide
Treatment Outcome
Substances
Antineoplastic Agents
lenalidomide
Thalidomide
Janus Kinase 2
JAK2 protein, human
PMID: 20846100
View Full Text